189 related articles for article (PubMed ID: 23264594)
1. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Kubovcakova L; Lundberg P; Grisouard J; Hao-Shen H; Romanet V; Andraos R; Murakami M; Dirnhofer S; Wagner KU; Radimerski T; Skoda RC
Blood; 2013 Feb; 121(7):1188-99. PubMed ID: 23264594
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
4. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
5. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
6. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
7. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
8. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
9. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
[TBL] [Abstract][Full Text] [Related]
10. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
11. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
12. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
13. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
[TBL] [Abstract][Full Text] [Related]
15. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.
Zalcberg IR; Ayres-Silva J; de Azevedo AM; Solza C; Daumas A; Bonamino M
Haematologica; 2011 Mar; 96(3):e18-20. PubMed ID: 21357711
[No Abstract] [Full Text] [Related]
17. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
19. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
Amaru Calzada A; Pedrini O; Finazzi G; Leoni F; Mascagni P; Introna M; Rambaldi A; Golay J;
Exp Hematol; 2013 Mar; 41(3):253-60.e2. PubMed ID: 23111067
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
